


CLINICAL PRACTICE GUIDELINE OPEN ACCESS

Clinical Practice Guideline for the Management of Communication and Swallowing in Children Diagnosed With Childhood Brain Tumor or Leukemia

Kimberley M. Docking¹  | Rosemary Hodges^{1,2}  | Lani Campbell¹  | Sara Chami¹  | Stefani R. Knijnik¹  | Emma Campbell^{1,3}  | Philippe Paquier^{4,5,6}  | Luciano Dalla-Pozza⁷  | Claire E. Wakefield^{8,9}  | Mary-Clare Waugh^{10,11}  | Maria Messina¹² | Angela T. Morgan^{13,14,15} 

¹Discipline of Speech Pathology, Faculty of Medicine and Health, The University of Sydney, Sydney, New South Wales, Australia | ²Western Sydney Speech Pathology, Sydney, New South Wales, Australia | ³New South Wales Health, Western Sydney Local Health District, Sydney, New South Wales, Australia | ⁴Vrije Universiteit Brussel, Brussel, Belgium | ⁵Université Libre de Bruxelles, Bruxelles, Belgium | ⁶Universiteit Antwerpen, Antwerpen, Belgium | ⁷Cancer Centre for Children at The Children's Hospital at Westmead, Sydney, New South Wales, Australia | ⁸School of Clinical Medicine, Medicine & Health, Randwick Clinical Campus, Discipline of Paediatrics, University of New South Wales, Sydney, New South Wales, Australia | ⁹Behavioural Sciences Unit, Kids Cancer Centre, Sydney Children's Hospital, Sydney, New South Wales, Australia | ¹⁰The Children's Hospital at Westmead, Sydney, New South Wales, Australia | ¹¹School of Medicine, Faculty of Medicine & Health, The University of Sydney, Sydney, New South Wales, Australia | ¹²Mary MacKillop College, Wakeley, Sydney, New South Wales, Australia | ¹³Murdoch Children's Research Institute, Melbourne, Victoria, Australia | ¹⁴The University of Melbourne, Melbourne, Victoria, Australia | ¹⁵The Royal Children's Hospital, Melbourne, Victoria, Australia

Correspondence: Kimberley M. Docking (kimberley.docking@sydney.edu.au)

Received: 8 September 2024 | **Revised:** 27 March 2025 | **Accepted:** 12 April 2025

Keywords: brain tumor | children | communication | language | leukemia | speech

ABSTRACT

Childhood brain tumor and leukemia (CBTL) and their treatments can have negative effects on development, including communication and swallowing. Clinical practice guideline recommendations for managing communication and swallowing difficulties in children diagnosed with CBTL were informed by (i) a systematic review using the GRADE approach to rate certainty of evidence; (ii) GRADE Evidence to Decision Framework involving an international panel of experts; and (iii) a Health Professional and Consumer survey. To improve outcomes and quality of life, children with CBLT should have access to communication and swallowing assessment and intervention from cancer diagnosis, throughout and after treatment, and across survivorship.

1 | Introduction

The developing brain is extremely fragile and susceptible to the impact of childhood brain tumor and leukemia (CBTL), the leading forms of cancer in children in developed countries worldwide [1–5] and the effects of required treatments [6–8].

Many effects resulting from central nervous system (CNS)-targeted treatments are not realized until many years later [9–13] due to late-occurring structural and functional changes in the brain [14–16]. These deleterious changes can appear any time up to 10–20 years post-treatment, potentially interrupting normal development in children who face the largest proportion of

Abbreviations: ANZCHOG, Australian and New Zealand Children's Haematology/Oncology Group; CBTL, childhood brain tumor and leukemia; CNS, central nervous system; EtD, Evidence to Decision; GRADE, Grading of Recommendations, Assessment, Development and Evaluations; NHMRC, National Health and Medical Research Council; PRISMA, Preferred Reporting Items for Systematic Reviews and Meta-Analyses; SWiM, Synthesis Without Meta-analysis guidelines.

This is an open access article under the terms of the [Creative Commons Attribution-NonCommercial](https://creativecommons.org/licenses/by-nc/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.

© 2025 The Author(s). *Pediatric Blood & Cancer* published by Wiley Periodicals LLC.

their lives post-cancer [8, 17]. While not all negative treatment effects have been avoided, modern treatment protocols have been adapted to minimize side effects whilst maintaining high cure rates [18]. Here, we focus on the impacts seen on communication development and swallowing skills.

Children diagnosed with CBTL are at risk for developing a range of communication difficulties in critical foundation skills, including speech and language skills such as understanding instructions, vocabulary, producing sentences, correct grammar, and reading and writing [9, 10, 14, 19–25]. Cognitive-communication and social language difficulties are also evident, impacting functional abilities such as problem-solving, story-telling, understanding jokes and sarcasm, conversation-level skills, social skills, initiating and maintaining friendships, and job readiness [10, 14, 26–32]. Communication difficulties have been reported for up to 81% of survivors of major childhood cancers [33]. Critically, verbal and nonverbal language skills that are yet to develop are most vulnerable, with young children in particular experiencing difficulty acquiring or developing skills at the expected rate after cancer treatment across developmental milestones [16, 17]. Missed schooling and reduced time spent socializing with peers can also exacerbate communication difficulties for children with CBTL [34–36]. However, early intervention can minimize or prevent communication deficits that occur following treatment for childhood brain cancer or leukemia [37].

Children diagnosed with CBTL commonly experience swallowing difficulties [38]. These challenges may include impairments with biting, chewing, clearing food effectively from the mouth, difficulty with food and fluid consistencies, fatigue during eating, uncoordinated swallowing, and/or the absence of a cough reflex to clear an obstruction [24, 38, 39]. Swallowing difficulties most frequently occur during and as a result of CNS cancer treatments (e.g., due to mouth ulcers). Difficulties may also persist longer term, with impacts to social and mealtime management, as well as potential life-threatening impacts from swallowing related to choking and chest infections [24, 39]. Poor management of swallowing can also lead to malnutrition and compromise development [38].

The long-term burden of CBTL can weigh on families, communities, and the health system, including costs that are associated with primary and ongoing healthcare services [40, 41]. It is vital that cancer cure includes optimization of quality of life for children and families surviving brain cancer and leukemia [9]. To optimize patient care, communication and swallowing management should be tailored to the needs of the child and family, with good coordination between team members [42]. An experienced and highly competent multidisciplinary team involved in the rehabilitation of children with brain tumor or leukemia may contribute to quality assurance of the overall treatment and follow-up programs [43]. Here, we advocate for a systematic, evidence-based approach to the management of communication and swallowing in children diagnosed with CBTL through clinical practice guideline recommendations. Clinical guidelines address the potential inequality of services provided for these children within or across centers, which may be perpetuated when a standardized approach does not exist [44]. Guidelines also assist health professionals to provide and advocate for evidence-based care and management and to educate patient consumers (parents

and patients) and support them to advocate for best practice management of communication and swallowing difficulties.

2 | Guideline Development

The clinical practice guideline was developed according to the 2016 National Health and Medical Research Council (NHMRC) Standards for Guidelines [45].

2.1 | Guideline Development Committee

2.1.1 | Panel of Experts (Steering Committee)

The Panel of Experts (Steering Committee) consisted of five members with research and/or clinical expertise in CBTL (AM, CW, PP, MW, LD), and one consumer (MM; parent of a child diagnosed with CBTL), and the Lead Development Group (Chair [KD], Project Coordinator [RH], and Research and Evidence Consultant [LC]). The role of the Panel of Experts was to provide input and feedback across all phases of guideline development, including clinical question development, systematic review, evidence synthesis, survey development, and development of the recommendations. Members of the Panel of Experts were invited to the role by the Chair or through a call for interest via the Australian and New Zealand Children's Haematology/Oncology Group (ANZCHOG).

2.2 | Health Professional and Consumer Group

The Health Professional and Consumer Group consisted of 22 multidisciplinary health professionals with experience in CBTL and two consumers (parents of children diagnosed with CBTL). The role of Health Professional and Consumer Group members was to complete an online survey to gather their perspectives and input into the clinical management of communication and swallowing in children diagnosed with CBTL. Recruitment, demographic information, including years of practice, employment, setting/s, disciplines, expertise and experience, and survey procedures are detailed in Chami et al. [46].

2.3 | Clinical Questions

Two clinical questions were developed to guide the evidence review for guideline recommendations. The questions were consistent with the PICOTS (population, intervention, comparison, outcome, timing, setting) format [47] (see Table 1).

The population of CBTL is inherently diverse, due to a range of presentation characteristics. Diversity includes differences in cancer diagnoses, cancer treatments, cancer treatment effects (during and after), age at diagnosis, as well as progression of disease, periods of admission, medical complications (e.g., increased intracranial pressure, infections), family circumstances, and values. In this guideline, brain tumor and leukemia were considered as one population (i.e., childhood brain tumor or leukemia) due to the similarities in CNS-targeted cancer treatments and outcomes for these groups. Both cancer

TABLE 1 | PICOTS^a clinical questions used to develop clinical practice guideline recommendations.

Communication outcomes	<i>What are the communication outcomes associated with childhood brain tumor or leukemia?</i>
Swallowing outcomes	<i>What are the swallowing outcomes associated with childhood brain tumor or leukemia?</i>

^aPICOTS format—population (P): children aged 0–16 with brain tumor or leukemia; intervention (I): any; comparison (C): any; outcome (O): communication/swallowing; timing (T): at diagnosis prior to cancer treatment, during the cancer treatment phase, during the cancer follow-up phase, during the survivorship phase; setting (S): both inpatient and outpatient settings.




FIGURE 1 | Framework of timing and setting in childhood brain tumor/leukemia.

groups commonly receive CNS-applied chemotherapy and/or radiotherapy that are reported to impact the developing brain and CNS [18]. However, a majority of the evidence on which the guideline recommendations are based was noted to be more largely represented by reports of children with brain tumor, with a recent increase in the amount of leukemia studies.

The scope of the guideline focuses on children aged 0–16 years. The 16-year age limit represents the upper age limit commonly applied to patients receiving pediatric services in the Australian healthcare system where the guideline originated.

2.4 | Timing and Setting Framework in Childhood Brain Tumor or Leukemia

The course of CBTL was conceptualized over time based on a long-term approach to health and well-being. Research focusing on communication and swallowing skills in this population examined outcomes at one or more points in time across a child’s cancer journey, from diagnosis through to survivorship. To provide consistency in describing these time points, a framework was developed that identifies four key pediatric oncology phases (see Figure 1):

1. At diagnosis/pre-treatment: at cancer diagnosis, prior to the start of cancer treatment
2. Cancer treatment phase: during, or in the weeks after, cancer treatment
3. Follow-up phase: less than 5 years since cancer treatment has finished

4. Survivorship phase: defined here as ≥ 5 years since cancer treatment has finished

These phases are closely linked with setting, including site-specific, country, and individual care practices. While some studies examine outcomes when children diagnosed with CBTL are still in hospital, others do so in community settings, such as clinics, schools, and at home. For simplicity in the framework, setting was binary classified into: “hospital–inpatient” and “after hospital–outpatient/discharged.”

Due to the possibility of cancer recurrence, secondary cancer/s, or multiple primary cancer/s, it is important to recognize that a child may return to an earlier phase in this framework.

2.5 | Evidence That Informed the Guideline

The evidence-based recommendations in this guideline as well as the key practice points were informed by three sources of evidence:

1. Systematic review, including Grading of Recommendations, Assessment, Development and Evaluations (GRADE) Certainty of Evidence ratings and outcomes (narrative synthesis methods)
2. International Panel of Experts (Steering Committee) of research/clinical experts and a consumer using the GRADE Evidence to Decision (EtD) Framework
3. Health Professional and Consumer Group survey

2.6 | Systematic Review

The systematic review followed reporting guidelines for the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statements [48], including the Synthesis Without Meta-analysis (SWiM) guidelines [49].

Systematic review methods are detailed in our original systematic review [50], including materials and methods such as information sources, search strategy, inclusion/exclusion criteria, study selection, data extraction, quality assessment of individual studies, and quality assessment of the body of evidence (certainty of evidence). The date range was expanded to December 19, 2024, and results updated here as follows.

2.6.1 | Study Selection

The updated PRISMA flowchart is shown in Figure S1. All 68 included studies and outcomes are detailed in Table S1 (communication) and Table S2 (swallowing).

2.6.2 | Characteristics of Included Studies

The characteristics of included studies specific to outcome are detailed, respectively, in Table S1 (communication) and Table S2 (swallowing). Study designs for included studies, participants,

and prognostic factors (cancer diagnoses) by outcome are summarized in Figures S2–S4.

2.6.3 | Data Synthesis

As noted in our original systematic review [50], due to heterogeneity of studies in terms of design and outcome measures, a narrative synthesis, not meta-analysis, was conducted. Narrative synthesis was guided by the SWiM guidelines designed for the reporting of methods and results in narrative systematic reviews [49]. Narrative summaries for each outcome (communication: speech, language, speech+language; and swallowing) were guided by predefined items [50] as shown in Table S3.

2.6.4 | Quality Assessment and GRADE Certainty of Evidence

The Joanna Briggs Institute (JBI) critical appraisal tools were used to assess the quality of each individual study [51, 52], resulting in a numerical score (see Tables S4–S7; individual quality assessment: speech, language, speech+language, swallowing). Individual study appraisal indicated methodological shortcomings in a majority of studies.

The body of evidence (GRADE) certainty rating for all outcomes (communication: speech, language, speech+language; swallowing) was determined by unanimous consensus by all authors as “very low.” For each outcome, the GRADE parameters contributing to the GRADE certainty rating were risk of bias and precision, as well as study design (as detailed in Tables S4–S7; GRADE certainty of evidence: speech, language, speech+language, swallowing).

2.6.5 | GRADE Summary of Findings Per Outcome (Narrative Summaries)

The GRADE summary of findings of the systematic review per outcome (communication, swallowing) are presented in Tables S8 and S9.

2.7 | GRADE Evidence to Decision Framework

GRADE Evidence to Decision (EtD) frameworks were completed by the Panel of Experts. The completed EtD frameworks and Summary of Judgments to Final Recommendations for Communication and Swallowing are detailed in full in Tables S10 and S11. The GRADE EtD framework provides a structured approach to ensure that judgments are reported transparently [53] (<https://www.gradeworkinggroup.org/>). The framework aims to determine the strength of recommendation, integrating the systematic review findings with prespecified criteria. This process included question formulation, making an assessment of the evidence, and drawing conclusions [53]. Input from the GRADE EtD Panel of Experts was gathered using a combination of online modes that are reported to be an effective method of engaging experts in the GRADE EtD process [54]. Neutral recommen-

dations were developed based on the clinical questions. These clinical questions were provided by the Lead Development Team to the Panel of Experts to consider. For communication, the neutral recommendation was: “Communication assessment and intervention should/should not be offered to children diagnosed with CBTL.” For swallowing, the neutral recommendation was: “Swallowing assessment and management should/should not be offered to children diagnosed with CBTL.”

The GRADE EtD framework was presented to the Panel of Experts via an online package developed by the Lead Guideline Development team using the software program, Typeform (<https://www.typeform.com/>). This online package guided the Panel of Experts through the evidence assessment process. Systematic review methods and findings were presented in two PowerPoint presentations (communication and swallowing) with an audio-recorded voiceover that provided details of the methods and summarized key findings from each of the systematic reviews.

The Panel of Experts were each asked to assess the evidence by providing detailed opinions and judgments about the GRADE EtD criteria in an online questionnaire, which included the GRADE EtD criteria (problem, desirable effects, undesirable effects, values, balance of effects, resources required, cost-effectiveness, equity, acceptability, feasibility) and consisted of both multiple choice and open question/answer formats to capture individual responses.

All nine (100%) Typeform GRADE EtD online questionnaires were returned complete. Responses were collated into the GRADE EtD framework format. All judgments (multiple-choice answers) and full comments from the Panel of Experts were included for each judgment area of the GRADE EtD framework. Multiple-choice judgments were tallied by majority; however, raw numbers (judgment of each member of the Panel of Experts) were also retained.

The GRADE EtD summary of judgments from the Panel of Experts informed the final recommendations and determined the strength of recommendations. The final two recommendations for both communication and swallowing were unanimously agreed upon (as detailed in Tables S10 and S11, GRADE EtD framework and summary of judgments).

2.8 | Health Professional and Consumer Group Survey

The final source of evidence that informed the guideline was a survey of health professionals and consumers that also informed guideline development [46]. Health professionals with clinical experience with CBTL were eligible. Eligible consumers were adult (≥ 18 years old) survivors of CBTL or parents of children/adolescents diagnosed with CBTL. The clinical questions were presented in three sections: (i) assessment and management of communication and swallowing issues in children with CBTL; (ii) multidisciplinary care (health professional involvement); and (iii) risk factors regarding CBTL and when they should

be considered by speech pathologists assessing and managing communication and swallowing disorders in this population [46].

No studies examining risk factors were identified in the systematic review. However, survey findings [46] highlighted the importance of providing comprehensive communication and swallowing assessment and intervention, and the need for this to be offered over time following CBTL diagnosis into the survivorship phase. Findings also supported a multidisciplinary approach to management of communication and swallowing in CBTL, during cancer treatment and beyond. Finally, a range of risk factors was identified, with the findings highlighting the need to provide individualized care that is tailored to the patient in terms of their individual characteristics (child factors), their cancer, and treatment factors (see Table S12; risk factors identified by the Health Professional and Consumer Group).

2.9 | Public Consultation and Guideline Approval

The guideline underwent public consultation and consultation with the Director-General, Chief Executive, and Secretary of each State, Territory, and Commonwealth Department of Health in Australia. Independent peer-reviews using the Agree II instrument [55] and methodological review were conducted by the National Health and Medical Research Council (NHMRC). The guideline recommendations were approved by the Chief Executive Officer of the NHMRC, under Section 14A of the National Health and Medical Research Council Act 1992.

3 | Evidence-Based Recommendations and Key Practice Points

3.1 | Communication Recommendation

The communication recommendation and key practice points are presented in Table 2.

3.1.1 | Strength of Communication Recommendation

Based on the GRADE EtD framework, this recommendation was rated as strong. The Panel of Experts was confident that the desirable effects of adherence to the recommendation outweighed the undesirable effects. The implications of a strong recommendation for patients, clinicians, and policymakers as identified by GRADE [56] are:

- for patients—most people in your situation would want the recommended course of action and only a small proportion would not; request discussion if the intervention is not offered;
- for clinicians—most patients should receive the recommended course of action; and
- for policymakers—the recommendation can be adopted as a policy in most situations.

3.1.2 | Evidence for Communication Recommendation

The systematic review unambiguously demonstrated the existence of communication difficulties in this population. Communication disorders were frequently reported in children diagnosed with CBTL [50], and may be present at the time of cancer diagnosis [21, 24] and/or during the cancer treatment phase [20, 57]. However, communication disorders may also be seen in the longer term, months or years after cancer treatment has been completed [22, 58, 59].

Communication disorders were evident across multiple subdomains of speech and language [50]. Dysarthria or specific speech deficits reported in this population included prosodic deficits [19, 21, 60–62], poor articulation/speech intelligibility [19, 21, 25, 61–63], slow rate [19, 25, 60, 63], and voice problems [19, 20, 25, 33, 61–65]. Fluency disorders have also been identified [21, 33, 66]. Mutism and/or dysarthria following surgery for cerebellar tumor surgery are well documented, including postoperative pediatric cerebellar mutism syndrome (pCMS) [19, 24, 25, 33, 57, 60–82]. For some children, mutism may resolve to dysarthria and/or language difficulties [24, 60, 63, 65, 69, 73, 77, 79, 80]. In the leukemia population, specific speech disorders have not been identified, but general disorders in speech have been reported [20, 59]. Identified language disorders included verbal language skills [14, 19–22, 33, 58–60, 69–71, 79, 80, 82–87], word-finding [60, 69, 84], narrative (story-telling) skills [26], and high-level language skills (e.g., inferencing, metaphors, jokes, and problem solving) [14, 23, 58, 85–88]. Literacy difficulties were also reported [19, 23, 33, 58, 89–91].

However, there are a various distinct limitations related to this body of evidence. First, there has been a reliance on descriptive study designs with small sample sizes. Second, heterogeneity across the literature in study design, participant factors, outcome measures, and timing of assessment makes it challenging to determine the prevalence of communication difficulties in this population. Third, there is limited evidence related specifically to children with leukemia as an emerging focus area.

Essential communication assessment and intervention in children diagnosed with CBTL was also recognized in evidence systematically gathered from the Health Professional and Consumer survey [46]. Communication skills were identified as critical foundations for later academic success, social connectedness, and mental health. The potential for cascading effects into adulthood with impacts on employment and participation in society was also highlighted. Outcomes from the Health Professional and Consumer survey study [46] emphasized a tailored and individualized approach as essential to communication management for children with CBTL, due to the heterogeneity in clinical presentations, medical management, and risk factors. Identified risk factors included child factors (e.g., age, socioeconomic background, hospital stay), brain tumor properties (e.g., location, size), and cancer treatment received (e.g., treatment type/combination, frequency) (see Table S12).

The desirable effects of providing communication assessment and intervention were rated by the Panel of Experts as large (see Table S10). The desirable effects focused on the improved communication outcomes that could be achieved if assessment

TABLE 2 | Communication recommendation and key practice points.

Evidence-based recommendation 1: Communication	
Communication assessment and intervention should be offered to children diagnosed with childhood brain tumor or leukemia	Strong recommendation ^a
Key practice points	
Assessment and intervention	
When to assess	
Communication assessment should occur at or as soon as possible after cancer diagnosis	
Communication assessment should occur during the cancer treatment phase and oncology follow-up phase. Multiple assessments during these phases may be required if concerns are indicated by the oncology care team and/or family	
Regular monitoring of the child's communication development should continue throughout the survivorship phase until the end of adolescence	
What to assess	
A comprehensive assessment of speech and language should be conducted. Assessment needs to be tailored to the age and developmental level of the child. Where appropriate, language assessment should include high-level language, discourse-level skills, and literacy	
Assessment should include a range of individualized assessment procedures such as norm-referenced assessments, criterion-referenced tools, caregiver report, and clinical observations across environments	
When to intervene	
Children diagnosed with CBTL should be provided with early individualized intervention during the cancer treatment phase for identified communication difficulties	
Children diagnosed with CBTL should be provided with timely individualized intervention for communication difficulties identified during the oncology follow-up and survivorship phases through until the end of adolescence	
Care team	
Speech pathologists should be involved as integral members of the oncology care team from the point of cancer diagnosis and throughout the cancer treatment and follow-up phases	
All members of the oncology care team should be informed about communication difficulties and involved in management throughout the cancer treatment and follow-up phases	
Speech pathologists should work in partnership with oncologists, family members, and education professionals to monitor communication development throughout the survivorship phase until the end of adolescence	
Education	
Education about communication development and difficulties in CBTL should be provided to families at cancer diagnosis or as early as possible	
Education about communication development and difficulties in CBTL should continue to be provided to families throughout the cancer treatment and follow-up phases	
Education about potential long-term communication difficulties in CBTL should be provided to families and education professionals throughout the oncology follow-up and survivorship phases	

^aBased on GRADE EtD framework.

and intervention were routinely offered to all children with downstream benefits for improved quality of life, particularly for social and academic participation. The undesirable effects were rated as small. These related to feelings of stress, worry, or frustration that could be experienced by the child or family in relation to testing and communication being “*just one more thing to worry about.*” Desirable effects were overwhelmingly rated as outweighing undesirable effects.

3.1.3 | Evidence for Key Practice Points: Communication

Evidence for the communication key practice points is detailed in Table S13; including when to assess and when to monitor communication skills in CBTL (Figure S5) and the areas of communication to be considered for assessment in CBTL (Figure S6).

TABLE 3 | Swallowing recommendation and key practice points.

Evidence-based recommendation 2: swallowing	
Swallowing assessment and management should be offered to children diagnosed with childhood brain tumor or leukemia	Strong recommendation ^a
Key practice points	
Assessment and intervention	
When to assess	
Swallowing assessment should occur at or as soon as possible after diagnosis of CBTL	
Swallowing assessment should occur during the cancer treatment phase. Multiple assessments may be required where concerns are indicated by the oncology care team and/or family	
Regular monitoring of the child's swallowing should continue throughout the oncology follow-up and survivorship phases until the end of adolescence	
What to assess	
A comprehensive swallowing assessment should be conducted. Assessment needs to be tailored to the age and developmental level of the child. All phases of the swallow (pre-oral anticipatory, oral-preparatory, oral, and pharyngeal) need to be assessed	
Videofluoroscopy should be considered on a case-by-case basis as part of the assessment protocol to examine aspiration	
When to intervene	
Children diagnosed with CBTL should be provided with early individualized management for swallowing difficulties during the cancer treatment phase	
Children diagnosed with CBTL should be provided with individualized management for swallowing difficulties identified by the oncology care team and/or family in the oncology follow-up and survivorship phases	
Care team	
Speech pathologists should be involved as integral members of the oncology care team from the point of cancer diagnosis and throughout the cancer treatment phase to manage swallowing	
All members of the oncology care team should be informed about swallowing difficulties and involved in their management as needed throughout oncology phases	
Speech pathologists should work in partnership with oncologists and family members to monitor swallowing throughout the survivorship phase until the end of adolescence	
Education	
Education about swallowing difficulties in CBTL should be provided to families at cancer diagnosis or as early as possible	
Education about swallowing difficulties in CBTL should continue to be provided to families throughout the cancer treatment and follow-up phases	

^aBased on GRADE EtD framework.

3.2 | Swallowing Recommendation

The swallowing recommendation and key practice points are presented in Table 3.

3.2.1 | Strength of Swallowing Recommendation

Based on the results of the GRADE EtD framework, this recommendation was rated as strong. The Panel of Experts was confident that the desirable effects of adherence to the recommendation outweighed the undesirable effects. The implications of a strong recommendation for patients, clinicians, and policymakers as identified by GRADE [56] are consistent with those outlined above for communication.

3.2.2 | Evidence for Swallowing Recommendation

It was clear from the systematic review that swallowing difficulties are present in children with CBTL and are frequently seen immediately or soon after cancer treatment. Swallowing disorders are frequently reported in children with CBTL [50]. Disorders are most likely to be experienced during cancer treatment [33, 92]. For some children diagnosed with CBTL, particularly children diagnosed with brain tumor, swallowing disorders may continue for longer term [24, 57].

Acute swallowing disorders in children with CBTL are typically characterized by deficits across the oral preparatory and oral phase (e.g., reduced lip seal, food/liquid residue post-swallow,

food spillage/drooling, impaired transfer of food in mouth) and the pharyngeal phase of the swallow (e.g., delayed initiation of swallow, food/liquid residue in pharynx, coughing/gurgly voice, aspiration) [20, 24, 39]. General clinical factors or pre-oral anticipatory factors that can impact swallowing ability, such as fatigue and alertness/awareness may also be affected [24, 39] and therefore need to be assessed. When children are receiving cancer treatment, swallowing disorders can be severe, with aspiration of food or liquids possible [92, 93]. As a result, supplemental tube feeding may be required [20, 24, 38, 39, 57].

However, there are limitations in the body of evidence that need to be considered. To date, studies have relied on descriptive designs and relatively small samples. Heterogeneity across studies in relation to participant factors, outcome measures, and timing of assessments limit the ability to draw conclusions about the prevalence of swallowing difficulties in this population. Furthermore, there is a lack of evidence related specifically to the swallowing outcomes of children with leukemia.

Essential swallowing assessment and management for children diagnosed with CBTL was also reflected in evidence systematically gathered from experts, health professionals, and consumers [46]. The possibility of swallowing difficulties resulting in aspiration and being life-threatening was emphasized. Ensuring adequate nutrition in the acute period was also highlighted. Longer term swallowing difficulties and their potential to influence quality of life were also recognized, such as the impact on independence, family mealtimes, and social eating/fitting in with peers at school.

This source of evidence also emphasized the need to consider the heterogeneity of clinical presentation and medical management in the CBTL population when providing swallowing management [46]. Consideration of risk factors was seen to be particularly important, including child factors (e.g., age, socioeconomic background, hospital stay), swallowing-related factors (e.g., prolonged tube feeding, poor physical positioning), tumor properties (e.g., cancer location, brain tumor size), and cancer treatment (e.g., treatment type/combination, frequency) (outlined in Table S12). Given the inherent diversity in this population, swallowing assessment and management should be offered to all children diagnosed with CBTL in the context of an individualized approach.

Desirable effects of providing swallowing assessment and management were rated as large by the Panel of Experts, such as the safe swallowing of fluids and food and the prevention of aspiration and subsequent health complications such as chest infections and pneumonia (see Table S11). The undesirable effects were rated as small and related to the potential for stress/anxiety related to assessment for children and their families. The desirable effects of providing assessment and management were therefore rated as outweighing undesirable effects.

3.2.3 | Evidence for Key Practice Points: Swallowing

Evidence for swallowing key practice points is detailed in Table S14, and when to assess and when to monitor swallowing skills in CBTL are outlined in Figure S7.

3.3 | Implications for Clinical Practice: GRADE EtD Framework

The GRADE EtD framework provided valuable context about the likely impact of recommendations on clinical practice and the health system. As part of the GRADE EtD framework, the Panel of Experts considered the five factors that weigh the risk versus benefit of the guideline recommendations (resources required, costeffectiveness, equity, acceptability, feasibility). The implications for clinical practice per outcome are described, respectively, in Tables 4 and 5.

4 | DISCUSSION

This clinical practice guideline has been developed to provide recommendations for multidisciplinary health professionals involved in the management of communication and swallowing disorders for children diagnosed with childhood brain tumor or leukemia, and families of children with CBTL. They are to be used alongside clinician judgment and patient preferences. Given the inherent diversity in this population, communication and swallowing assessment and intervention should be offered to all children diagnosed with CBTL in the context of an individualized approach to management. These recommendations are based on the best available evidence. Relevant health professionals may include, but are not limited to, speech pathologists, oncologists, rehabilitation physicians, nurses, occupational therapists, physiotherapists, dietitians, child life therapists, psychologists, and music therapists. Education providers in educational settings will also benefit from evidence-based guidelines to support CBTL survivors to transition back into the classroom and school community for educational services.

These guidelines will equip parents and families as lifelong advocates in seeking optimal quality-of-life outcomes for their children by providing knowledge about difficulties their child may experience and what these difficulties might look like over the course of development and beyond. This will ensure that families are connected with timely management, early intervention services, and appropriate referral services [94].

The impact of communication and swallowing disorders on quality of life beyond childhood, adolescence, and into adulthood is also acknowledged. Impacts are worse when early intervention and management are not provided. Adult survivors of childhood cancer may experience barriers to educational achievement as well as an impact to mental health, vocational independence, and earning potential [40, 41, 95].

The evidence unambiguously demonstrated the existence of communication disorders in this population. It was also clear that swallowing disorders can affect children with CBTL and are frequently seen immediately or soon after cancer treatment, particularly in children with brain tumor. There are limitations in the body of evidence that need to be considered. Studies have relied on descriptive designs and relatively small samples. There was significant heterogeneity across studies in relation to study design, participant factors, outcome measures, and timing of assessments. These heterogeneous factors limit the ability to draw robust conclusions about the prevalence of communication

TABLE 4 | Implications of communication recommendation for clinical practice: GRADE EtD framework.

Implications for clinical practice	Summary of judgments and comments from GRADE EtD framework
Resources required	<p>Costs and savings</p> <p>The Panel of Experts (Steering Committee) determined it is likely that there would be both costs and savings related to offering communication assessment/intervention to all children diagnosed with CBTL. Possible costs in the short-term may relate to the employment and upskilling of staff. However, there are potential long-term savings for the health sector, disability sector, education sector, and families due to reduced impact of communication difficulties long-term.</p>
Cost effectiveness	<p>Favors providing assessment/intervention</p> <p>The Panel of Experts (Steering Committee) determined that communication assessment/intervention would be more cost effective compared to no communication assessment/intervention.</p> <p>The short-term costs of offering communication/intervention are likely to be small compared to long-term costs of treating more established disorders later in development. The cost benefits also extend to psychological, educational, and employment outcomes.</p>
Equity	<p>Increased</p> <p>The Panel of Experts (Steering Committee) determined that equity would likely to be increased if communication assessment/intervention was offered to children diagnosed with CBTL. If the recommended minimum standard via a national guideline was implemented, communication assessment/intervention would become routine. This would allow greater access to communication assessment/intervention, regardless of factors such as cultural and linguistic diversity, non-English-speaking backgrounds, socioeconomic status, geographical location, and education levels.</p>
Acceptability	<p>Yes</p> <p>The Panel of Experts (Steering Committee) determined that offering communication assessment/intervention would be acceptable to the majority of stakeholders, including families and health professionals.</p>
Feasibility	<p>Yes</p> <p>The Panel of Experts (Steering Committee) determined that offering communication assessment/intervention would be feasible to incorporate into current services. There are few issues with regards to feasibility, except for funding and staffing resources.</p>

and swallowing disorders in this population. Furthermore, there is a lack of evidence related specifically to the communication and swallowing outcomes of children with leukemia.

There is a clear need for larger scale studies with prospective longitudinal research designs examining communication and swallowing outcomes and intervention in children diagnosed with CBTL [50]. In particular, additional research focusing on communication outcomes in children diagnosed with leukemia is warranted. This includes further examination of communication disorders longitudinally across all timepoints and settings (e.g., diagnosis, during cancer treatment, oncology-follow-up, and survivorship). It is critical to co-design research with consumer partners, specifically focused on communication and swallowing outcomes of children from culturally, linguistically, socially, and geographically diverse communities. Recognition of diversity will ensure continued progress toward equitable and accessible services across all populations of children diagnosed with CBTL. Greater accuracy in identifying the prevalence of communication and swallowing disorders in children diagnosed with CBTL is also needed, as are larger scale studies focusing on effectiveness of communication and swallowing rehabilitation programs [50].

5 | CONCLUSION

The recommendations made in this guideline call for both communication and swallowing assessment and intervention to be offered to children diagnosed with brain tumor or leukemia.

Children diagnosed with brain tumor and leukemia often experience communication disorders such as difficulties producing clear speech, understanding and using language, and literacy skills. Communication disorders are common both at the time of cancer diagnosis and during cancer treatment, but are most commonly seen or arise in the months or years after cancer treatment.

Swallowing disorders are frequently reported during cancer treatment. However, there is evidence that swallowing disorders may continue longer term once cancer treatment has finished, particularly for children diagnosed with brain tumor. Feeding and swallowing contribute to quality of life, socialization, and family bonding, whereas the impaired ability to swallow foods and fluids can also be life-threatening, as it puts the child at risk of chest infections if food/fluid enters the lungs.

TABLE 5 | Implications of swallowing recommendation for clinical practice: GRADE EtD framework.

Implications for clinical practice	Summary of judgments and comments from GRADE EtD framework
Resources required	<p>Negligible costs</p> <p>The Panel of Experts (Steering committee) determined that there were negligible costs related to offering swallowing assessment/management to children diagnosed with CBTL. They recognized that the resources to provide assessment and management in the acute phases were already available; however, longer term follow-up could require additional resources in relation to staff, education, and assessment tools. Health professionals' time was the main resource identified.</p>
Cost effectiveness	<p>Favors providing assessment/management</p> <p>The Panel of Experts (Steering Committee) determined that swallowing assessment/management would be more cost effective compared to no swallowing assessment/management. Providing management was seen as outweighing the potential negative impacts of swallowing difficulties related to aspiration, chest infection, and hospital stay length.</p>
Equity	<p>Increased</p> <p>The Panel of Experts (Steering Committee) determined that equity would be likely to be increased if swallowing assessment/management was offered to children diagnosed with CBTL. In particular, equity may be increased for children from non-English-speaking backgrounds or lower socioeconomic backgrounds where families may be less able to identify swallowing difficulties or advocate for needs. One member of the Panel of Experts (Steering Committee) noted that more targeted approaches to identifying which children need swallowing assessment/management would be preferable to the current "status-quo."</p>
Acceptability	<p>Yes</p> <p>The Panel of Experts (Steering Committee) determined that offering swallowing assessment/management would be acceptable to the majority of stakeholders, including families and health professionals.</p>
Feasibility	<p>Yes</p> <p>The Panel of Experts (Steering Committee) determined that offering swallowing assessment/management would be feasible to incorporate into current services. However, they did recognize that this would depend on funding and staffing resources. It was recognized that it is not onerous and mostly requires time from the speech pathologist.</p>

The intended outcome of these evidence-based guideline recommendations is to improve the quality of life for children surviving brain tumor and leukemia. Guideline development has involved translating evidence from the research and clinical/consumer expertise into recommendations to guide improvements in cancer services and quality of clinical care for this population. Implementation of these recommendations will support a systematic and equitable approach to clinical management for communication and swallowing in CBTL, including long-term follow-up. Guidelines will inform targeted early intervention programs and survivorship surveillance planning. These recommendations will support children to keep healthy and lead a fulfilled life, not only during cancer diagnosis and treatment, but critically after cancer survival.

Acknowledgments

We would like to thank the Health Professional and Consumer group for their contributions to this project, in particular the parents of children diagnosed with brain tumor or leukemia.

Open access publishing facilitated by The University of Sydney, as part of the Wiley - The University of Sydney agreement via the Council of Australian University Librarians.

Disclosure

KD and AM were co-authors on a number of studies included in the systematic review that informed guideline development. Potential conflict of interest procedures were conducted, and KD and AM did not conduct appraisal of any individual studies.

Conflicts of Interest

The authors declare no conflicts of interest.

References

1. Australian Institute of Health and Welfare, *Cancer in Australia 2019* (AIHW, 2019).
2. Australian Institute of Health and Welfare, *Australia's Children* (AIHW, 2020).
3. Q. T. Ostrom, G. Cioffi, H. Gittleman, et al., "CBTRUS Statistical Report: Primary Brain and Other central Nervous System Tumors Diagnosed in the United States in 2012–2016," *Neuro-Oncology* 21, no. Supplement_5 (2019): v1–v100.
4. R. Siegel, C. DeSantis, K. Virgo, et al., "Cancer Treatment and Survivorship Statistics, 2012," *CA: A Cancer Journal for Clinicians* 62, no. 4 (2012): 220–241.

5. D. R. Youlden, P. D. Baade, A. C. Green, P. C. Valery, A. S. Moore, and J. F. Aitken, "The Incidence of Childhood Cancer in Australia, 1983–2015, and Projections to 2035," *Medical Journal of Australia* 212, no. 3 (2020): 113–120.
6. V. Anderson, M. Spencer-Smith, and A. Wood, "Do Children Really Recover Better? Neurobehavioural Plasticity After Early Brain Insult," *Brain* 134, no. 8 (2011): 2197–2221.
7. C. Shen, S. M. Perkins, J. A. Bradley, A. Mahajan, and K. J. Marcus, "Radiation Therapy for Infants With Cancer," *Pediatric Blood & Cancer* 68, no. S2 (2021): e28700.
8. S. P. Rodgers, M. Trevino, J. A. Zawaski, M. W. Gaber, and J. L. Leasure, "Neurogenesis, Exercise, and Cognitive Late Effects of Pediatric Radiotherapy," *Neural Plasticity* 2013 (2013): 698528.
9. K. Docking, B. Murdoch, and R. Suppiah, "The Impact of a Cerebellar Tumour on Language Function in Childhood," *Folia Phoniatrica Et Logopaedica* 59 (2007): 190–200.
10. K. Docking, P. Paquier, and A. Morgan, "Childhood Brain Tumour," in *Research in Clinical Pragmatics*, ed. L. Cummings (Springer-Verlag, 2017), 131–164.
11. P. Duffner, "Risk Factors for Cognitive Decline in Children Treated for Brain Tumors," *European Journal of Paediatric Neurology* 14, no. 2 (2010): 106–115.
12. M. Monje and P. Fisher, "Neurological Complications Following Treatment of Children With Brain Tumors," *Journal of Pediatric Rehabilitation Medicine* 4, no. 1 (2011): 31–36.
13. R. K. Mulhern, T. E. Merchant, A. Gajjar, W. E. Reddick, and L. E. Kun, "Late Neurocognitive Sequelae in Survivors of Brain Tumors in Childhood," *Lancet* 364, no. 9452 (2004): 399–408.
14. F. Lewis, B. Murdoch, and K. Docking, "An Investigation of General and High-level Language Skills in Children Treated With Central Nervous System-Targeted Chemotherapy for Acute Lymphoblastic Leukemia," *Journal of Medical Speech-Language Pathology* 19, no. 2 (2011): 27–36.
15. S. O'Neil, K. Walsh, D. Wallace, et al., "Neurocognitive Outcomes in Pediatric and Adolescent Patients With central Nervous System Germinoma Treated With a Strategy of Chemotherapy Followed by Reduced-dose and Volume Irradiation," *Pediatric Blood & Cancer* 57, no. 4 (2011): 669–673.
16. M. Ris, K. Walsh, D. Wallace, et al., "Intellectual and Academic Outcome Following Two Chemotherapy Regimens and Radiotherapy for Average-Risk Medulloblastoma: COG A9961," *Pediatric Blood & Cancer* 60, no. 8 (2013): 1350–1357.
17. K. S. Walsh and I. Paltin, Neuropsychological Effects of Pediatric Brain Tumors and Associated treatment, in *Handbook of Long-Term Care of the Childhood Cancer Survivor*, ed. G. A. Mucc and L. R. Torno (Springer Science + Business Media, 2015), 249–262.
18. E. Chang, R. Goldsby, S. Mueller, A. Banerjee, "Late Effects of Treatment and Palliative care," in *Pediatric CNS Tumors*, ed. N. Gupta, A. Banerjee, and D. Haas-Kogan (Springer, 2017).
19. F. K. Aarsen, H. R. Van Dongen, P. F. Paquier, M. Van Mourik, and C. E. Catsman-Berrevoets, "Long-Term Sequelae in Children After Cerebellar Astrocytoma Surgery," *Neurology* 62, no. 8 (2004): 1311–1316.
20. O. Taylor, R. Ware, and K. Weir, "Speech Pathology Services to Children With Cancer and Nonmalignant Hematological Disorders," *Journal of Pediatric Oncology Nursing* 29, no. 2 (2012): 98–108.
21. D. Chieffo, G. Tamburrini, M. Caldarelli, and C. Di Rocco, "Preoperative Neuropsychological and Behavioral Evaluation of Children With Thalamic Tumors: Clinical Article," *Journal of Neurosurgery: Pediatrics* 113, no. 5 (2014): 507–513.
22. K. Docking, B. Murdoch, and E. Ward, "General Language Abilities Following Management of Childhood Supratentorial Tumour: Part I," *Acta Neuropsychologica* 1, no. 3 (2003): 260–283.
23. K. Docking, B. Murdoch, and E. Ward, "High-Level Language and Phonological Awareness Abilities of Children Following Management for Supratentorial Tumour: Part II," *Acta Neuropsychologica* 1, no. 4 (2003): 367–381.
24. C. Mei and A. Morgan, "Incidence of Mutism, Dysarthria and Dysphagia Associated With Childhood Posterior Fossa Tumour," *Child's Nervous System* 27, no. 7 (2011): 1129–1136.
25. A. Morgan, F. Liégeois, C. Liederkerke, et al., "Role of Cerebellum in Fine Speech Control in Childhood: Persistent Dysarthria After Surgical Treatment for Posterior Fossa Tumour," *Brain & Language* 117, no. 2 (2011): 69–76.
26. K. Docking, N. Munro, T. Marshall, and L. Togher, "Narrative Skills of Children Treated for Brain Tumours: The Impact of Tumour and Treatment Related Variables on Microstructure and Macrostructure," *Brain Injury* 30, no. 8 (2016): 1005–1018.
27. D. J. Mabbott, L. Penkman, A. Witol, D. Strother, and E. Bouffet, "Core Neurocognitive Functions in Children Treated for Posterior Fossa Tumors," *Neuropsychology* 22, no. 2 (2008): 159.
28. L. S. Kahalley, H. M. Conklin, V. L. Tyc, et al., "Slower Processing Speed After Treatment for Pediatric Brain Tumor and Acute Lymphoblastic Leukemia," *Psycho-Oncology* 22, no. 9 (2013): 1979–1986.
29. F. K. Aarsen, P. F. Paquier, W. Arts, et al., "Cognitive Deficits and Predictors 3 Years After Diagnosis of a Pilocytic Astrocytoma in Childhood," *Journal of Clinical Oncology* 27, no. 21 (2009): 3526–3532.
30. K. Docking, E. Ward, and B. Murdoch, "Language Outcomes Subsequent to Treatment of Brainstem Tumour in Childhood," *Neurorehabilitation* 20, no. 2 (2005): 107–124.
31. A. Papazoglou, T. Z. King, R. D. Morris, M. K. Morris, and N. S. Krawiecki, "Attention Mediates Radiation's Impact on Daily Living Skills in Children Treated for Brain Tumors," *Pediatric Blood & Cancer* 50, no. 6 (2008): 1253–1257.
32. T. Reimers, E. Mortensen, and K. Schmiegelow, "Memory Deficits in Long-Term Survivors of Childhood Brain Tumors May Primarily Reflect General Cognitive Dysfunctions," *Pediatric Blood & Cancer* 48, no. 2 (2007): 205–212.
33. M. Goncalves, T. C. Radzinsky, N. S. da Silva, B. M. Chiari, and D. Consonni, "Speech-Language and Hearing Complaints of Children and Adolescents With Brain Tumors," *Pediatric Blood & Cancer* 50, no. 3 (2008): 706–708.
34. A. Lum, C. E. Wakefield, B. Donnan, et al., "School Students With Chronic Illness Have Unmet Academic, Social, and Emotional School Needs," *School Psychology* 34, no. 6 (2019): 627.
35. B. M. Donnan, T. Webster, C. E. Wakefield, et al., "What About School? Educational Challenges for Children and Adolescents With Cancer," *Educational and Developmental Psychologist* 32, no. 1 (2015): 23–40.
36. J. K. McLoone, C. E. Wakefield, P. Butow, C. Fleming, and R. J. Cohn, "Returning to School After Adolescent Cancer: A Qualitative Examination of Australian Survivors' and Their Families' perspectives," *Journal of Adolescent and Young Adult Oncology* 1, no. 2 (2011): 87–94.
37. R. Skinner, R. Haupt, L. Hjorth, L. Kremer, and R. L. Mulder, "The European Experience of Establishing Guidelines for Surveillance of the Childhood Cancer Survivor," in *Handbook of Long Term Care of the Childhood Cancer Survivor*, G. Mucci and L. Torno (Springer, 2015), 25–35.
38. W. H. Lee, B. Oh, H. G. Seo, et al., "One-year Outcome of Postoperative Swallowing Impairment in Pediatric Patients With Posterior Fossa Brain Tumor," *Journal of Neuro-Oncology* 127, no. 1 (2016): 73–81.
39. A. T. Morgan, D. Sell, M. Ryan, E. Raynsford, and R. Hayward, "Pre and Post-Surgical Dysphagia Outcome Associated With Posterior Fossa Tumour in Children," *Journal of Neuro-Oncology* 87, no. 3 (2008): 347–354.
40. J. Bell, R. Lingam, C. E. Wakefield, et al., "Prevalence, Hospital Admissions and Costs of Child Chronic Conditions: A Population-Based Study," *Journal of Paediatrics & Child Health* 56, no. 9 (2020): 1365–1370.

41. E. Cohen, J. G. Berry, X. Camacho, G. Anderson, W. Wodchis, and A. Guttman, "Patterns and Costs of Health Care Use of Children With Medical Complexity," *Pediatrics* 130 (2012): 1463–1470.
42. P. Paquier, K. S. Walsh, K. M. Docking, H. Hartley, R. Kumar, and C. E. Catsman-Berrevoets, "Post-Operative Cerebellar Mutism Syndrome: Rehabilitation Issues," *Child's Nervous System* 36, no. 6 (2020): 1215–1222.
43. I. Van't Hooft, A. Lindahl Norberg, A. Björklund, M. Lönnblad, and B. Strömberg, "Multiprofessional Follow-Up Programmes Are Needed to Address Psychosocial, Neurocognitive and Educational Issues in Children With Brain Tumours," *Acta Paediatrica* 105, no. 6 (2016): 676–683.
44. A. Morgan and J. Skeat, "Evaluating Service Delivery for Speech and Swallowing Problems Following Paediatric Brain Injury: An International Survey," *Journal of Evaluation in Clinical Practice* 17 (2011): 275–281.
45. NHMRC, "2016 NHMRC Standards for Guidelines," NHMRC, 2016, <https://www.nhmrc.gov.au/guidelinesforguidelines/standards>.
46. S. Chami, R. Hodges, E. Campbell, S. R. Knijnik, and K. Docking, "Communication and Swallowing Management in Childhood Brain Tumor or Leukemia: A Survey of Health Professionals and Consumers," *International Journal of Speech-Language Pathology* 24, no. 4 (2021): 395–406.
47. R. Riley, K. G. M. Moons, K. I. E. Snell, et al., "A Guide to Systematic Review and Meta-analysis of Prognostic Factor Studies," *BMJ* 364 (2019): k4597.
48. D. Moher, A. Liberati, J. Tetzlaff, and D. G. Altman, "Preferred Reporting Items for Systematic Reviews and Meta-analyses: The PRISMA Statement," *PLOS Medicine* 6, no. 7 (2009): e1000097.
49. M. Campbell, J. E. McKenzie, A. Sowden, et al., "Synthesis Without Meta-analysis (SWiM) in Systematic Reviews: Reporting Guideline," *BMJ* 368 (2020): l6890.
50. R. Hodges, L. Campbell, S. Chami, S. R. Knijnik, and K. Docking, "Communication and Swallowing Outcomes of Children Diagnosed With Childhood Brain Tumor or Leukemia: A Systematic Review," *Pediatric Blood & Cancer* 68, no. 2 (2021): e28809.
51. M. Mueller, M. D'Addario, M. Egger, et al., "Methods to Systematically Review and Meta-analyse Observational Studies: A Systematic Scoping Review of Recommendations," *BMC Medical Research Methodology* 18, no. 1 (2018): 44.
52. Z. Munn, S. Moola, K. Lisy, D. Riitano, and C. Tufanaru, "Methodological Guidance for Systematic Reviews of Observational Epidemiological Studies Reporting Prevalence and Cumulative Incidence Data," *International Journal of Evidence-Based Healthcare* 13, no. 3 (2015): 147–153.
53. P. Alonso-Coello, H. J. Schünemann, J. Moher, et al., "GRADE Evidence to Decision (EtD) Frameworks: A Systematic and Transparent Approach to Making Well Informed Healthcare Choices. 1: Introduction," *BMJ* 353 (2016): i2016.
54. H. Van Remoortel, E. de Buck, M. M. Mueller, et al., "How Can We Enhance Shared Decision Making in an International Guideline Project?," in *EBHC International Conference*, 2019, Sicily, Italy.
55. AGREE Next Steps Consortium, "The AGREE II Instrument," AGREE Enterprise, 2017, <http://www.agreetrust.org>.
56. H. Schünemann, *GRADE Handbook for Grading Quality of Evidence and Strength of Recommendations* (GRADEpro, 2013), gdt.guidelinedevelopment.org/app/handbook/handbook.html.
57. E. Brannon Morris, C. Li, R. B. Khan, et al., "Evolution of Neurological Impairment in Pediatric Infratentorial Ependymoma Patients," *Journal of Neuro-Oncology* 94, no. 3 (2009): 391–398.
58. K. Docking, B. Murdoch, and E. Ward, "Underlying Factors Impacting Differential Outcomes in Linguistic Function Subsequent to Treatment for Posterior Fossa Tumour in Children," *Brain & Language* 91, no. 1 (2004): 29–30.
59. J. Levy, T. Tello, R. Giller, et al., "Late Effects of Total Body Irradiation and Hematopoietic Stem Cell Transplant in Children Under 3 Years of Age," *Pediatric Blood & Cancer* 60, no. 4 (2013): 700–704.
60. C. Catsman-Berrevoets and F. Aarsen, "The Spectrum of Neurobehavioural Deficits in the Posterior Fossa Syndrome in Children After Cerebellar Tumour Surgery," *Cortex* 46, no. 7 (2010): 933–946.
61. P. Cornwell, B. Murdoch, and E. Ward, "Differential Motor Speech Outcomes in Children Treated for Mid-line Cerebellar Tumour," *Brain Injury* 19, no. 2 (2005): 119–134.
62. P. Cornwell, B. E. Murdoch, E. C. Ward, and S. Kellie, "Perceptual Evaluation of Motor Speech Following Treatment for Childhood Cerebellar Tumour," *Clinical Linguistics & Phonetics* 17, no. 8 (2003): 597–615.
63. H. J. De Smet, C. Catsman-Berrevoets, F. Aarsen, J. Verhoeven, P. Mariën, and P. F. Paquier, "Auditory-perceptual Speech Analysis in Children With Cerebellar Tumours: A Long-Term Follow-Up Study," *European Journal of Paediatric Neurology* 16, no. 5 (2012): 434–442.
64. P. L. Cornwell, B. E. Murdoch, E. C. Ward, and S. Kellie, "Acoustic Investigation of Vocal Quality Following Treatment for Childhood Cerebellar Tumour," *Folia Phoniatrica Et Logopaedica* 56, no. 2 (2004): 93–107.
65. M. Van Mourik, C. E. Catsman-Berrevoets, E. Yousef-Bak, P. F. Paquier, and H. R. van Dongen, "Dysarthria in Children With Cerebellar or Brainstem Tumors," *Pediatric Neurology* 18, no. 5 (1998): 411–414.
66. J. F. Huber, K. Bradley, B. Spiegler, and M. Dennis, "Long-Term Neuromotor Speech Deficits in Survivors of Childhood Posterior Fossa Tumors: Effects of Tumor Type, Radiation, Age at Diagnosis, and Survival Years," *Journal of Child Neurology* 22, no. 7 (2007): 848–854.
67. S. Beckwith Turkel, M. D. Krieger, S. O'Neil, R. Jubran, and C. J. Tavaré, "Symptoms Before and After Posterior Fossa Surgery in Pediatric Patients," *Pediatric Neurosurgery* 48, no. 1 (2012): 21–25.
68. C. Catsman-Berrevoets, H. R. Van Dongen, P. G. Mulder, D. Paz y Geuze, P. F. Paquier, and M. H. Lequin, "Tumour Type and Size Are High Risk Factors for the Syndrome of 'Cerebellar' mutism and Subsequent Dysarthria," *Journal of Neurology, Neurosurgery & Psychiatry* 67, no. 6 (1999): 755–757.
69. H. J. De Smet, H. Baillieux, P. Wackenier, et al., "Long-Term Cognitive Deficits Following Posterior Fossa Tumor Resection: A Neuropsychological and Functional Neuroimaging Follow-Up Study," *Neuropsychology* 23, no. 6 (2009): 694–704.
70. C. Di Rocco, D. Chieffo, P. Frassanito, M. Caldarelli, L. Massimi, and G. Tamburrini, "Heralding Cerebellar Mutism: Evidence for Pre-surgical Language Impairment as Primary Risk Factor in Posterior Fossa Surgery," *Cerebellum (London, England)* 10, no. 3 (2011): 551–562.
71. C. Di Rocco, D. Chieffo, B. L. Pettorini, L. Massimi, M. Caldarelli, and G. Tamburrini, "Preoperative and Postoperative Neurological, Neuropsychological and Behavioral Impairment in Children With Posterior Cranial Fossa Astrocytomas and Medulloblastomas: The Role of the Tumor and the Impact of the Surgical Treatment," *Child's Nervous System* 26, no. 9 (2010): 1173–1188.
72. B. Frank, B. Schoch, C. Hein-Kropp, et al., "Verb Generation in Children and Adolescents With Acute Cerebellar Lesions," *Neuropsychologia* 45, no. 5 (2007): 977–988.
73. M. P. Korah, N. Esiashvili, C. M. Mazewski, et al., "Incidence, Risks, and Sequelae of Posterior Fossa Syndrome in Pediatric Medulloblastoma," *International Journal of Radiation Oncology Biology Physics* 77, no. 1 (2010): 106–112.
74. K. Kotil, M. Eras, M. Akçetin, and T. Bilge, "Cerebellar Mutism Following Posterior Fossa Tumor Resection in Children," *Turkish Neurosurgery* 18, no. 1 (2008): 89–94.
75. S. Kupeli, B. Yalçın, B. Bilginer, N. Akalan, P. Haksal, and M. Büyükpamukçu, "Posterior Fossa Syndrome After Posterior Fossa Surgery in Children With Brain Tumors," *Pediatric Blood & Cancer* 56, no. 2 (2011): 206–210.

76. J. Liu, R. A. Dineen, S. Avula, et al., "Development of a Pre-Operative Scoring System for Predicting Risk of Post-operative Paediatric Cerebellar Mutism Syndrome," *British Journal of Neurosurgery* 32, no. 1 (2018): 18–27.
77. A. Ozimek, S. Richter, C. Hein-Kropp, et al., "Cerebellar Mutism: Report of Four Cases," *Journal of Neurology* 251, no. 8 (2004): 963–972.
78. S. Richter, B. Schoch, A. Ozimek, et al., "Incidence of Dysarthria in Children With Cerebellar Tumors: A Prospective Study," *Brain & Language* 92, no. 2 (2005): 153–167.
79. D. Riva, "The Cerebellum Contributes to Higher Functions During Development. Evidence From a Series of Children Surgically Treated for Posterior Fossa Tumours," *Brain* 123, no. 5 (2000): 1051–1061.
80. P. Robertson, K. M. Muraszko, E. J. Holmes, et al., "Incidence and Severity of Postoperative Cerebellar Mutism Syndrome in Children With Medulloblastoma: A Prospective Study by the Children's Oncology Group," *Journal of Neurosurgery* 105, no. Suppl. 6 (2006): 444–451.
81. E. Wells, Z. P. Khademian, K. S. Walsh, et al., "Postoperative Cerebellar Mutism Syndrome Following Treatment of Medulloblastoma: Neuro-radiographic Features and Origin," *Journal of Neurosurgery* 5, no. 4 (2010): 329–334.
82. J. A. Grieco, A. N. Abrams, C. L. Evans, T. I. Yock, and M. B. Pulsifer, "A Comparison Study Assessing Neuropsychological Outcome of Patients With Post-Operative Pediatric Cerebellar Mutism Syndrome and Matched Controls After Proton Radiation Therapy," *Child's Nervous System* 36, no. 2 (2020): 305–313.
83. B. Frank, B. Schoch, C. Hein-Kropp, et al., "Aphasia, Neglect and Extinction Are no Prominent Clinical Signs in Children and Adolescents With Acute Surgical Cerebellar Lesions," *Experimental Brain Research* 184, no. 4 (2008): 511–519.
84. L. Levisohn, A. Cronin-Golomb, and J. Schmahmann, "Neuropsychological Consequences of Cerebellar Tumour Resection in Children: Cerebellar Cognitive Affective Syndrome in a Paediatric Population," *Brain* 123, no. 5 (2000): 1041–1050.
85. F. Lewis and B. Murdoch, "Language Outcomes Following Risk-adapted Treatments for Tumors Located Within the Posterior Fossa," *Journal of Child Neurology* 26, no. 4 (2011): 440–452.
86. F. Lewis and B. Murdoch, "Differential Language Trajectories Following Treatment for Pediatric Posterior Fossa Tumor: An Investigation of Four Cases," *Neurorehabilitation* 32, no. 1 (2013): 165–183.
87. F. Fabbro, B. E. Murdoch, K. M. Docking, and E. C. Ward, "Language and Phonological Awareness Abilities of Children Treated for Posterior Fossa Tumor," in *Neurogenic Language Disorders in Children* ed. F. Fabbro (Elsevier, 2004), 87–126.
88. F. Lewis and J. Bohan, "Early Adolescent Language Development Following Intrathecal Chemotherapy for Acute Lymphoblastic Leukaemia," *International Journal of Speech-Language Pathology* 20, no. 5 (2018): 485–493.
89. N. Ait Khelifa-Gallois, S. Puget, A. Longaud, et al., "Clinical Evidence of the Role of the Cerebellum in the Suppression of Overt Articulatory Movements During Reading. A Study of Reading in Children and Adolescents Treated for Cerebellar Pilocytic Astrocytoma," *Cerebellum (London, England)* 14, no. 2 (2015): 97–105.
90. L. Lafay-Cousin, E. Bouffet, C. Hawkins, A. Amid, A. Huang, and D. J. Mabbott, "Impact of Radiation Avoidance on Survival and Neurocognitive Outcome in Infant Medulloblastoma," *Current Oncology* 16, no. 6 (2009): 21–28.
91. M. Lönnerblad, R. Lovio, E. Berglund, and I. van't Hooft, "Affected Aspects Regarding Literacy and Numeracy in Children Treated for Brain Tumors," *Journal of Pediatric Oncology Nursing* 34, no. 6 (2017): 397–405.
92. L. A. Newman, F. A. Boop, R. A. Sanford, J. W. Thompson, C. K. Temple, and C. D. Duntsch, "Postoperative Swallowing Function After Posterior Fossa Tumor Resection in Pediatric Patients," *Child's Nervous System* 22, no. 10 (2006): 1296–1300.
93. P. Nagy, N. Beckmann, S. Cox, and A. Sheyn, "Management of Vocal Fold Paralysis and Dysphagia for Neurologic Malignancies in Children," *Annals of Otolaryngology, Rhinology & Laryngology* 128, no. 11 (2019): 1019–1022.
94. A. Feraco, S. R. Brand, J. W. Mack, J. C. Kesselheim, S. D. Block, and J. Wolfe, "Communication Skills Training in Pediatric Oncology: Moving Beyond Role Modeling," *Pediatric Blood & Cancer* 63, no. 6 (2016): 966–972.
95. L. Delaney and J. Smith, "Childhood Health: Trends and Consequences Over the Life Course," *Future of Children* 22, no. 1 (2012): 43–63.

Supporting Information

Additional supporting information can be found online in the Supporting Information section.